Capricor Therapeutics Inc.

Products

Category

Product

Brand

Description

Exosome Diagnostics, Therapeutics and Research Tools (BIO149E)

StealthX Exosome platform		Exosome platform for designer protein surface expression, cargo loading and targeted delivery. Capricor Therapeutics is currently exploring its deployment in two broad modalities: precision therapeutics and vaccinology.
CAP-2003 Exosomes product candidate		Exosomes derived from cardiosphere-derived cells (CDCs). In 2020, Capricor Therapeutics submitted an IND with the U.S. FDA to investigate the use of CAP-2003 in patients with DMD. The FDA has requested more information regarding manufacturing for CAP-2003.The company has only conducted preclinical studies with its exosome technologies and none of its exosome-based candidates have been approved for clinical investigation.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment